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The Thrombosis Centre, Gentofte University Hospital, Hellerup, DenmarkObjectives. To investigate the results of catheter directed thrombolysis offered to patients with acute femoro-iliac deep
venous thrombosis (DVT).
Design. Retrospective analysis of all patients treated with this modality at Gentofte Hospital until December 2003.
Material. Forty-five consecutive patients treated between June 1999 and December 2003 with a median age of 31 years. All
patients had femoro-iliac DVT with an average anamnesis of 6 days.
Methods. All patients were treated by catheter directed infusion of alteplase into the popliteal vein. After thrombolysis
residual venous stenoses were treated by percutaneous balloon angioplasty (PTA) and stenting. Patients were followed with
color-duplex scanning for assessment of venous patency and reflux.
Results. Forty-two of 45 (93%) of cases were treated successfully with reopening of the thrombosed vein segments. In 30 of
45 cases a residual stenosis was treated by PTA and stenting. Only one serious complication was observed: Compartment
syndrome of the forearm where arterial punctures had been taken. After an average of 24 months follow-up were no cases of
re-thrombosis among the 42 patients discharged with open veins. Only two of 41 with presumed normal venous valve
function prior to DVT developed reflux during follow-up.
Conclusion. In this selected patient group, catheter directed thrombolysis seems effective in treating acute DVT, it appears
durable and preserves venous valve function in the majority. The method needs to be tested in a randomised controlled trial.Keywords: Deep venous thrombosis; Thrombolysis; Venous reflux; Deep venous insufficiency.Introduction
Deep venous thrombosis (DVT) remains the primary
pathogenetic mechanism for development of chronic
deep venous insufficiency (CDVI), which may result in
chronic pain, oedema and ultimately venous ulcera-
tion of the lower limb. Also, DVT may in the acute
phase give rise to pulmonary embolism, which in
worst case may be fatal. Treatment in the acute phase
is directed towards prevention of further thrombosis
and pulmonary embolism and significant risk
reduction may be obtained by anticoagulation with
heparins and warfarin. On long term, anticoagulation
may be continued if the patient has increased risk of
recurrence of DVT, i.e. because of hemostaticng author. Henrik Sillesen, MD, DMSc, Chairman,
f Vascular Surgery, Rigshospitalet, Blegdamsvej 9, DK
agen O, Denmark.
: henrik.sillesen@rh.dk
0556 + 07 $35.00/0 q 2005 Elsevier Ltd. All rights reserdisorders. However, CDVI develops in many patients
after DVT and with serious symptoms affecting quality
of life in 33–87%.1–6
The pathogenetic mechanism for development of
CDVI may be either that of venous reflux due to
destruction and/or insufficiency of the venous valves
or due to chronic venous obstruction. In either case,
venous hypertension develops and results in the above
mentioned symptoms. Because venous thrombi in the
majority of cases are partly or totally autolysed within a
few months, venous reflux is by far the most common of
the two mechanisms, since, the venous valves most
often are destructed during the recanalisation process.7
Venous thrombectomy and systemic thrombolysis
was performed experimentally for many years,
however, their true value was never convincingly
proven in randomised controlled trials. In the only
published randomised trial, Plate et al. showed that,
although the operated group (venous thrombectomy)Eur J Vasc Endovasc Surg 30, 556–562 (2005)
doi:10.1016/j.ejvs.2005.06.012, available online at http://www.sciencedirect.com onved.
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anticoagulation, none of the two groups did very
well in the long run.8 In recent years, a number of
reports has indicated that local thrombolysis, directed
through an intravenous catheter into the venous clot,
resulted in successful lysis of the thrombus and high
percentage of the reopened veins appeared patent
within the first year.9–13 Lately also venous reflux
appears to be avoided in the majority of patients
treated with local thrombolysis.13–15 Only one small,
randomised trial with 6 months follow-up has been
published indicating that DVT treated with thrombo-
lysis results in superior patency and better preser-
vation of valve function.15
The main goal of treatment of DVT should be to
prevent CDVI on long term, thus, not only patency of
the thrombolysed vein segments is of relevance,
venous valve function may be at least as important.
In 2002, we published our initial experience with our
first 12 patients treated with local catheter-directed
venous thrombolysis.13 We had an initial success rate
of 83% and found all lysed veins being patent with
normal venous valve function at 5 months follow-up
(median). The present study reports our experience
during the first 4.5 years where we have offered local
thrombolysis in selected cases with femoro-iliac
venous thrombosis.Material and Methods
The first of the 45 consecutive patients in this study
was treated 16th of June 1999 and the last December
3rd 2003. Seven were males and 38 females, with a
median age of 31 years (range 15–57 years). All
patients had femoro-iliac DVT and had accepted
treatment with catheter-directed thrombolysis, a
treatment that had been described for them as being
on experimental basis.
All patients were referred with diagnosed deep
venous thrombosis mainly from departments of
internal medicine, in hospitals from all over the
country. Only patients with a short anamnesis (!
approximately 14 days) without obvious contraindica-
tions for thrombolysis were seen. On admission, all
patients were seen by a consultant in vascular surgery
and a specialist in haemostasis in order to assess the
clinical history and status of the patient.
Inclusion criteria for thrombolysis were DVT
involving the ilio-femoral segment and an anamnesis
!2 weeks. Also, one deep vein was required to be
open in the popliteal fossa since, our technique relied
on the catheter being introduced through the popliteal
vein.Exclusion criteria included the following: Age O60
years, malignancy or other concomitant chronic or
potential life-threatening disease, bleeding disorders,
uncontrolled hypertension and recent surgery. Also,
patients with a history of previous ipsilateral DVT or
CDVI were excluded.Investigations prior to thrombolysis
On admission patients were examined by color-
Doppler ultrasound for assessment of the venous
system. Patients fulfilling the inclusion criteria were
informed about the treatment options including that
local thrombolysis was an offer and that this treatment
remains experimental without proven long-term
results. Patients were informed about a small risk of
pulmonary embolism and systemic bleeding in
addition to the possibility of local complications in
the region of puncture (poples). Prior to thrombolysis
all patients were given low molecular weight heparin
(tinzaparin) 100 IE per kg twice daily and oral
anticoagulant therapy initiated at the referring hospi-
tal was discontinued. The heparin dosage was
adjusted according to anti-Xa levels.
Patients accepting thrombolysis were screened for
thrombosis promoting factors by evaluation of factor V
Leiden mutation, protrombin mutation 20210, protein
C, protein S, antithrombin, plasminogen, anticardioli-
pin antibodies, lupus anticoagulans and homocystein.
In addition, INR, platelets, fibrinogen, D-Dimer,
activated partial thromboplastin time (APTT), hemo-
globin, creatinine, sodium and potassium was assessed.
All patients with pulmonary symptoms had pul-
monary scintigrams performed prior to and after
thrombolytic therapy.
The diagnosis of DVT was confirmed by a
venogram performed by direct puncture of the
popliteal vein (see below). In this manner the precise
extension of the DVT could be estimated. The
contralateral iliac venous system was examined either
by ultrasonography or by venography to secure the
run-off on this side and the presence of an open vena
cava (one case with partial aplasia of the vena cava
was eventually treated, see below). In doubt of the
presence of a normal vena cava a CT scan was
performed. If a CT scan was not performed an
abdominal ultrasound examination was done to
exclude major tumours or other masses that could
compress the venous system.
In the angiosuite, the popliteal vein was punctured
using ultrasound guidance allowing for introduction of
a lysis catheter. In the beginning we used a double
catheter—coaxial catheter system (Mewissen InfusionEur J Vasc Endovasc Surg Vol 30, 11 2005
Table 1. Extension of thrombus prior to thrombolysis
Venous segments with thrombus
I 5
ICF 34
ICFCP 4
F 1
FCP 1
I, iliac vein; F, femoral vein; P, popliteal vein.
H. Sillesen et al.558Catheter/Katzen Infusion Wire; Boston Scientific) with
the intention to infuse the thrombolytic fluid into most
of the thrombus. A starting dose of 1 mg alteplase
(rt-PA)C1000–5000 i.e. unfractionated heparin was
used followed by continuous infusion of 1 mg rt-PAC
1000 i.e. heparin per hour. Later (from patient number
10) a long lysis catheter with a tip occluder and side
holes over 40–50 cm was used (Pro Infusion Catheter;
AngioDynamics), covering most of the extension of the
thrombosis. Treatment started with ‘pulse-spray’ tech-
nique, where 10 mg rt-PAC1000–5000 i.e. heparin was
injected over the first 15–30 min in the attempt to
shorten the overall treatment period. Hereafter, throm-
bolysis continued as described with the first nine cases,
however, with the rt-PA dissolved in a larger volume of
fluid (100 ml/h). Initially, pulse spray was performed
manually for approximately 15 min by the radiologist;
during the last year of the present series an automatic
system was used in the ward additionally, which
continuously generated a pulse every 15 s.
Control venograms were performed every day and
when all clot had been lysed, and a stenosis maybe
uncovered, this was dilated and stented before
catheters were removed. In cases were all visible
thrombus had been lysed, but the D-Dimer remained
above 10 mg/l lysis was continued for 6–24 h.
During the period of i.v. infusion of rt-PA, the
patient remained in bed with a continuous com-
pression device on the calf (sequential compression
device: SCD pump).
Blood tests prior to treatment are mentioned above.
When rt-PA infusion was initiated, treatment was
monitored with APTT, thrombin time, fibrinogen, anti-
thrombin, fibrin D-Dimer, hemoglobin and platelets.
Depending on prior anticoagulant treatment INR or
anti-Xa was measured for adjustment of heparin
starting dosage. During treatment, heparin dosage
was adjusted to APTT between 80 and 100 s. After
lysis was terminated patients were started on warfarin
and was also treated with low molecular heparin
(tinzaparin) 100 IE per kg twice daily for 14 days.
Measurement for long graduated compression
stockings was taken using the healthy leg during
thrombolysis so the patient could be discharged with a
relevant compression.
Patients were followed up at regular intervals: After
6 weeks, 3, 6 and 12 months. Thereafter patients were
invited on a yearly basis. At follow-up patients were
seen by a consultant in vascular surgery, and a color-
Doppler investigation was performed to assess venous
patency in the horizontal position and valve function
(reflux) in the standing position. Reflux was assessed
in the femoral and popliteal veins and defined asEur J Vasc Endovasc Surg Vol 30, 11 2005retrograde flow following release of compression of
the calf muscles lasting more than 0.5 s.
At 1 year all patients were invited to a venogram.
All patients were treated with warfarin for at least
12 months. Only patients with high risk of re-
thrombosis (i.e. serious coagulant defects such as
antithrombin deficiency, homozygous factor V Leiden
mutation, protein C and S deficiencies etc.) remained
on warfarin.Results
Forty-three of the 45 patients had thrombosis involv-
ing the iliac veins. The two without iliac involvement
had thrombosis of the superficial femoral vein and one
also of the proximal popliteal vein. Five patients had
DVT confined only to the iliac veins (Table 1). There
were seven cases of right sided DVT and 38 left sided.
Despite our attempt to exclude patients with previous
DVT on the affected limb, three patients were
included: Two patients who revealed findings, which
during treatment were judged to be due to previous
DVT (one with remote symptoms not identified pre-
treatment, and one without any symptoms at all). One
patient had a history of ipsilateral femoral DVT 6 years
before the present episode—diagnosis confirmed by
venography. This patient had pathological fast venous
filling time, as assessed by venous pletysmography,
performed 5 years before the DVT qualifying for
thrombolysis. Also, one patient with partial aplasia of
the vena cava was treated since, her left leg was
severely affected by the thrombosis.
The duration of symptoms was in median 6 days
(1–14 days) and was used as the estimate of when the
thrombus had developed. In many cases the initial
symptom was pain in the groin, iliac fossa or lower
back appearing days before the actual swelling of the
limb. When assessing the time of symptoms we used
the first symptom, i.e. pain before swelling of the limb.
In nine cases the lower limb DVT was associated with
symptomatic pulmonary embolism.
There were no cases in which planned thrombolysis
was not conducted as planned. In only one case the
DVT Thrombolysis 559treatment was stopped early due to a complication
(compartment syndrome of the forearm—see below),
however, the thrombosis was lysed at that time and the
remaining stenosis was stented the following day.
The median time of treatment (infusion of rt-PA
including endovascular management) was 71 h (range
25–146 h). When lysis was completed, 30 of the 45
occluded veins (67%) revealed underlying stenoses in
the iliac veins. Two of the stenotic lesions were among
the seven (28%) patients with right sided DVT whereas
the remaining 28 were found among the 38 (74%) with
DVT on the left side. All were treated with balloon
angioplasty and stent (mainly Wall Stent, Boston
Scientific, but also Memotherm, Bard, and Smart
Stent, Cordis).
Technical success with re-opening of the deep
veins was obtained in 42 of 45 (93%) cases (Table 2).
Partial lysis and re-opening was obtained in two of
the last three cases: One case turned out to have
chronic superficial femoral vein (SFV) occlusion,
which was evident as the catheter barely could be
passed through the occlusion. By re-questioning the
patient he did actually have symptoms of previous
DVT of that leg. In addition to the chronically
occluded SFV the patient also had iliac vein
thrombosis, which was successfully dissolved. At
follow-up, the SFV has remained occluded but the
lysed iliac vein has remained patent at 49 months
follow-up. The second patient probably had a
chronic occlusion of the common iliac vein since,
thrombolysis of the femoral and external iliac vein
was successful and the patient became asympto-
matic also without reflux at follow-up. The last
patient underwent 120 h of rt-PA infusion and the
deep veins were partially re-opened, however, with
some residual thrombus remaining. This patient re-
thrombosed before discharge and no further
attempts were done.
Complications were observed in seven cases (16%),
however, only severe in one case. A 23-year-old
woman with pulmonary embolism secondary to her
DVT had arterial punctures taken in her left arm priorTable 2. Results of thrombolytic therapy after a median of 24
months follow-up
Number of pts. Treated 45
Technical success (thrombus lysed) 42 (93%)
Number of patients discharged with open deep
veins
42 (93%)
Number of re-occlusions after discharge 0
Number of patients without venous reflux 39 (96%)*
* One patient had pathologically fast venous refilling time
demonstrated 5 years before thrombolysis and thus, most probable
venous reflux already.to lytic therapy. After 16 h of thrombolysis she
developed compartment syndrome of her right
forearm, most probably due to the previous punctures
of the radial artery. Fasciotomy was performed and
later closed and the patient has no sequelae at 4
months follow-up. Additional four patients had minor
bleeding complications, however, in none so that it
prevented continued lysis. The bleeding was mainly
confined to the puncture site in the popliteal fossa and
in one case 6 days post partum some vaginal bleeding
occurred (not requiring transfusion). One patient had
a skin rash (erytema), however, the patient was
simultaneously treated with penicillin due to high
temperature. One patient re-thrombosed 2 days after
termination of 146 h lysis. This patient underwent re-
thrombolysis for 46 h before discharge and the deep
veins have remained open with normally functioning
valves at 24 months follow-up.
Hemostatic predisposing factors was identified in
30 of the 45 patients (67%), of whom 15 had two factors
(factor V Leiden heterozygote, lupus anticoagulans,
anticardiolipin antibodies, protein S deficiency, hyper-
homocysteinemia and prothrombin mutation).
Median follow-up time was 24 months (range 1–
51 months). All of the deep veins that were opened
in the 42 patients, who were discharged after
successful thrombolysis, remained patent at follow-
up. The two patients who could not be recanalysed
remained with chronic occlusions of their SVF and
common iliac veins, respectively. The patient with
chronic common iliac occlusion, who had her
femoral and external iliac veins re-opened by
thrombolysis was asymptomatic without reflux at
24 moths follow-up. The patient with chronic SFV
occlusion had tendency to oedema of the ipsilateral
lower limb and reflux had developed in the
popliteal vein (seen last 49 months after treatment).
In the 42 patients who had successful thrombolysis,
reflux was found in three patients. However, one of
these was the patient with previous DVT and short
venous filling time, as mentioned previously. In the
two others, with presumeably normal functioning
valves prior to DVT and thrombolysis, reflux was
discovered at 24 and 49 months follow-up. Thus, in
39 of 41 (96%) patients where venous valve function
presumably was normal before DVT, it remained
normal at follow-up. Interestingly, none of the three
patients with reflux presented any symptoms at
follow-up (40, 49 and 49 months).
The patient included with atresia of the vena cava
had the SFV and iliac veins opened and venous
drainage was through large lumbar veins. This patient
was asymptomatic without reflux 8 months after
treatment.Eur J Vasc Endovasc Surg Vol 30, 11 2005
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The presented results compare favourable with those
reported in the literature. Previous studies have
reported a primary success rate of 80–90% concerning
total or partial recanalisation of the thrombosed deep
veins. In a report from a national register Mewissen et
al.12 found a primary success rate of 83% although only
31% had total lysis of all thrombosed segments and
52% partial thrombolysis. Bjarnason et al. treated 77
patients with ilio-femoral DVT and without malignant
disease and obtained total or partial thrombolysis in
89%. We reopened the thrombosed deep veins in 93%
of cases; however, our patient material was highly
selected, probably accounting for our high primary
success rate. In our three failures, chronic occlusion of
some of the occluded venous segments may have
contributed to the lack of success in at least two of the
cases. It is well known that venous occlusion may
occur without symptoms, thus, our patients may have
been unaware of previous venous occlusive disease.
The patency rate was very good; all patients
discharged with open veins (93%) also had open
veins after the average of 2 years follow-up. Bjarnason
et al.11 reported a 2-year patency of 78% and Ly et al.14
found that all of those who initially had complete lysis
remained patent at 20 months whereas those with only
partial lysis had a lower patency rate. That our patency
rate seems superior to that reported by others is
probably due to a combination of our strict selection
criteria and that we chose to treat all remaining
stenoses by balloon angioplasty and stent. Ly et al.,14
who treated a comparable patient material, only used
endovascular treatment following lysis when a press-
ure gradient O3 mmHg was associated with the
remaining stenosis. Thus, only four of 28 (14%)
patients were treated endovascularly in this material
as compared to our 65% who were dilated and
subsequently stented.
Three studies have evaluated venous valve function
after thrombolysis. Elshawary and Elzayat found
significantly fewer (only two of 18 (11%)) to have
developed reflux 6 months after treatment with
thrombolysis as compared to seven (41%) in the
group treated with anticoagulation.15 Ly et al. reported
that nine of 28 (33%) developed reflux at 2 years
follow-up apparently related negatively to the degree
of lysis (less reflux the better degree of lysis).14 Laiho et
al.16 found 44% of treated patients to have preserved
venous valve function 2–3 years after treatment. We
experienced even better results since, only two of the
42 (4%) discharged with patent veins developed reflux
(one patient with reflux at follow-up most certainly
already had this at the time of thrombolytic therapy).Eur J Vasc Endovasc Surg Vol 30, 11 2005An explanation for this high degree of valve preser-
vation could be that our median time between first
symptoms and lytic therapy was only 7 days.
The fact that venous function remained preserved
after 2 years may indicate that the risk of developing
post thrombotic syndrome in long term may not be so
high for these patients. Serial ultrasound studies on
patients with newly developed DVT has shown that
reflux indeed develops within few months after the
acute thrombosis,7 a finding which could support a
good prognosis for patients undergoing successful
lysis with preserved venous valve function. Looking at
the patients who did develop reflux, one was among
the two who probably had a history of DVT, which
could account or contribute to the damage of the
venous valves.
Despite attempts to exclude patients with previous
DVT and vena cava atresia three patients were
included: Two with previous ipsilateral DVT and one
with vena cava atresia. In both cases with previous
DVT previous relevant symptoms were not clarified
on admission and in one case remote symptoms had
been present. The patient with vena cava atresia was
an 18-year-old girl with severe symptoms from the
affected limb where the femoral and iliac veins were
occluded. The thrombosed segments were success-
fully re-opened and she became asymptomatic with
normally functioning veins. The success in this case
probably reflects that treatment resulted in restoration
of her usual venous run-off.
Systemic thrombolysis has been performed in the
past but was never convincingly shown to be of major
benefit, although some improvement was reported in
single centre series. No randomised trial has been
published that has demonstrated a clear advantage
compared to conservative treatment with anticoagula-
tion alone. In a meta-analysis Comeraota et al. showed
that systemic thrombolysis resulted in significant or
complete lysis in 45% compared to only 4% of those
treated with anticoagulation. Thus, less patients will
develop CDVI after systemic thrombolysis as
compared to anticoagulation which, however, has
been reported in only to controlled trials, summarised
by Comerato.17 In a recent report, Laiho et al. followed
16 patients who had prior systemic thrombolysis and
16 patients who was treated with catheter directed
thrombolysis. Two to 3 years after the acute avent,
patients treated with catheter directed thrombysis
fared better both with respect to preserved venous
valve function and clinical symptoms.16 This was,
however, not a randomised trial.
In the only published randomised study venous
thrombectomy was shown to improve the long term
outcome in the operated group, however, still the
DVT Thrombolysis 561majority of the treated patients (60%) went on to
develop chronic venous insufficiency.8 Considering
that we found 65% to have an underlying stenosis after
lysis of the thrombus, one reason for the limited
success of venous thrombectomy could be that these
stenoses were left untreated and potentially caused re-
thrombosis at a later stage. The good results presented
in this study and by others do, however, not make it
tempting to undertake a comparative study between
catheter directed lysis and venous thrombectomy.
Even if the latter could result in the same rate of
technical success and long term patency and pre-
served venous function, it would seem unrealistic to
have as low a perioperative morbidity.
Another reason to favour catheter based thrombo-
lysis is the theoretical less damage to the venous
endothelium. In a study where thrombosis was
induced in the iliac vein in dogs, Cho et al. investigated
the effect of no treatment, venous thrombectomy and
catheter based thrombolysis.18 The experiment
showed that thrombolysis was the method, which
with least damage to the vessel wall and valve
function and least thrombogenicity resulted in reca-
nalisation of the vein.
There may be a number of reasons for the good
results obtained in our study. First of all, our patients
were highly selected. This policy was chosen since, we
were introducing a new and experimental treatment
algorithm to replace a safe and proven treatment:
Anticoagulation. Although it is well known that
anticoagulation alone does not prevent CVDI, it is
effective in preventing pulmonary embolism and
death. Thus, we wished to introduce catheter-based
thrombolysis with the highest possibility of success.
Finally, treatment of acute DVT is offered as a
combined effort by three departments: Department
of vascular surgery, department of radiology and the
thrombosis centre.
The findings of this study support those previously
published and clearly indicate that catheter based
thrombolysis may be a superior treatment compared
to anticoagulation alone. The present study adds to the
literature showing that not only may the opened veins
remain patent, the valve function remain preserved
making it tempting to believe that treated patients may
remain asymptomatic on long term. A study by
Comerato et al. even indicate that quality of life is
better after catheter directed thrombolysis when
compared to anticoagulation.19 However, despite
these promising results on short as well as long term,
randomised trials needs to be designed and con-
ducted. At present only one small trial has reported
early results indicating that catheter directed throm-
bolysis results in better outcome as compared toanticoagulation. Thirty-five patients were randomised
and both patency and venous valve function was
significantly better at 6 months follow up.15
In conclusion, although the literature quite clearly
indicates that catheter-based thrombolysis is superior
to anticoagulation in selected patients, other studies
will be needed to support the present data and to
identify the patients who will benefit from
thrombolysis.References
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